Before taking Bylvay(Odevixibat)

Important precautions include monitoring for liver toxicity, managing diarrhea, and addressing fat-soluble vitamin deficiencies.

Warnings and Monitoring

BYLVAY carries a risk of hepatotoxicity and drug-induced liver injury. Baseline liver tests are required, with frequent monitoring recommended during the initial 6-8 months of therapy. Persistent diarrhea should be managed, which may require dose interruption. Fat-soluble vitamin (A, D, E, K) levels should be monitored at baseline and periodically during treatment, with supplementation initiated if a deficiency is identified. The drug is contraindicated in patients with current or prior hepatic decompensation.